Impact of pemafibrate on lipid profile and insulin resistance in patients with statin-treated coronary artery disease with metabolic syndrome

Back

ESC Professional Premium Access

Impact of pemafibrate on lipid profile and insulin resistance in patients with statin-treated coronary artery disease with metabolic syndrome

Session: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

Topic: Lipid-Lowering Agents

Speaker: Doctor A. Nakamura (Morioka, JP)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Akihiro Nakamura

Iwate Prefectural Central Hospital, Morioka (Japan)

0 follower

5 more presentations in this session

Cross-sectional analysis of demographic and clinical characteristics of patients using icosapent ethyl

Speaker: Doctor J. Nelson (Fresno, US)

Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study

Speaker: Professor S. Yamashita (Izumisano, JP)

Comparing the drug target effects of Cholesteryl ester transfer protein (CETP) on cardiovascular diseases in East Asian and European populations

Speaker: Miss D. Dunca (London, GB)

RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys

Speaker: Professor L. Gan (Goteborg, SE)

Discovery and preclinical development of LY3473329, a potent small molecule inhibitor of lipoprotein(a) formation

Speaker: Doctor L. Michael (Indianapolis, US)

Access the full session

Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

Speakers: Doctor A. Nakamura, Doctor J. Nelson, Professor S. Yamashita, Miss D. Dunca, Professor L. Gan...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Impact of pemafibrate on lipid profile and insulin resistance in patients with statin-treated coronary artery disease with metabolic syndrome

About the speaker

Doctor Akihiro Nakamura

5 more presentations in this session

Cross-sectional analysis of demographic and clinical characteristics of patients using icosapent ethyl

Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study

Comparing the drug target effects of Cholesteryl ester transfer protein (CETP) on cardiovascular diseases in East Asian and European populations

RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys

Discovery and preclinical development of LY3473329, a potent small molecule inhibitor of lipoprotein(a) formation

Access the full session

Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates

About the event

ESC Congress 2023

ESC 365 is supported by